AbbVie’s etentamig meets dual primary endpoints in Phase 3 blood cancer study
AbbVie said its blood-cancer drug etentamig met dual primary endpoints in a Phase 3 study, including a significantly higher objective response rate and improvements in progression-free survival versus standard available therapies.
By Elias SchisgallAbbVie said a drug to treat blood cancer met its dual primary endpoints in a phase 3 study.The company said etentamig demonstrated a significantly higher objective response rate and improvements in progression-free survival over standard available therapies in patients with triple…